Guidelines on atopic dermatitis for Mexico (GUIDAMEX): using the ADAPTE methodology

• Published in: Gaceta médica de México Vol. 158; no. Suplement 2; p. 1
• Main Authors: Larenas-Linnemann, Désirée, Rincón-Pérez, Catalina, Luna-Pech, Jorge A, Macías-Weinmann, Alejandra, Vidaurri-de la Cruz, Helena, Navarrete-Rodríguez, Elsy M, Del Río-Navarro, Blanca E, Godínez-Alderete, Liliana, Guevara-Sanginés, Esther, Ortega-Martell, José A, Toledo-Bahena, Mirna E, Elizondo-Villareal, Bárbara, Madrigal-Beas, Ileana M, Amaya-Guerra, Mario, Barreras-Salcedo, José I, Boeta-Ángeles, Leticia, Campos-Rivera, Armando, Casillas-Guzmán, Martha E, Duarte-Abdala, Mario R, Espinosa-Padilla, Sara E, García-Rodríguez, Juan C, Gómez-Flores, Minerva, Gómez-Mendoza, Rubén A, Del C Lacy-Niebla, Rosa Ma, Miranda-Aguirre, Alessandra I, Olivares-Nolasco, Claudia, Onuma-Takane, Ernesto, Pérez-Luna, Mariana, Pliego-Reyes, Carlos L, Rodríguez-Aguilera, Ma de Lourdes, Sáez-de Ocariz-Gutiérrez, María Del Mar, Saucedo-Sánchez, Arturo, Sotelo-Ocampo, Ana B, Valencia-Herrera, Adriana Ma, Vázquez-García, Jorge, Wakida-Kuzunoki, Guillermo H, Camarillo-Saavedra, Jacqueline, Rodríguez Monroy, Fernanda A
• Format: Journal Article
• Language: Spanish
• Published: Mexico 20.01.2023
• Subjects: Comorbidity; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - therapy; Diagnosis, Differential; Humans; Mexico; Phototherapy - methods; Mexico; Flare; Atopic dermatitis; Dupilumab; Clinical practice guideline; Atopic eczema; JAK inhibitors
• ISSN: 0016-3813
• DOI: 10.24875/GMM.M22000690

With the advancement of knowledge in relation to the physiopathogenesis of atopic dermatitis (AD), several new therapeutic forms have been developed. There are also new guidelines for self-care. On the other hand, there is still an underdiagnosis of AD in Mexico. Thus, the need was seen to develop a national guide, with a broad base among the different medical groups that care for patients with AD. The Atopic Dermatitis Guidelines for Mexico (GUIDAMEX) was developed with the ADAPTE methodology, with the endorsement and participation of ten national medical societies, from physicians in Primary Healthcare to allergists and dermatologists. Throughout the manuscript, key clinical questions are answered that lead to recommendations and suggestions for the diagnosis of AD (including differential diagnosis with immunodeficiency syndromes), the recognition of comorbidities and complications, non-pharmacological treatment including therapeutic education, treatment of flares and maintenance therapy. The latter encompasses general measures to avoid triggering factors, first-line treatment focussed on repair of the skin barrier, second-line treatment (topical proactive therapy), and third-line phototherapy or systemic treatment, including dupilumab and JAK inhibitors.